Cargando…

Editorial: Altered epigenetic modification mediated dysregulated transcriptional networks in drug resistance

Detalles Bibliográficos
Autores principales:	Brunetti, Bryce, Yoshida, Akihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160670/ https://www.ncbi.nlm.nih.gov/pubmed/37152020 http://dx.doi.org/10.3389/fonc.2023.1196448

Ejemplares similares

Editorial: Epigenetic Modifications in Mesothelioma
por: Cheng, Yuen Yee, et al.
Publicado: (2021)

Editorial: The Role of Epigenetic Modifications in Cancer Progression
por: Fujimura, Atsushi, et al.
Publicado: (2021)

Editorial: The interconnection between epigenetic modifications and the tumor microenvironment
por: He, Siyuan, et al.
Publicado: (2023)

Editorial: Epigenetic and Transcriptional Dysregulations in Cancer and Therapeutic Opportunities
por: Ansari, Rais A., et al.
Publicado: (2022)

Editorial: The role of epigenetic modification in radiotherapy and immuno-oncology in cancer: from bench to clinical application
por: Lin, Hon-Yi, et al.
Publicado: (2023)

Editorial: Transcriptional Regulation as a Key Player in Cancer Cells Drug Resistance
por: Martinez-Balibrea, Eva, et al.
Publicado: (2021)

Editorial: Interplay between epigenetic modifiers and transcription factors in driving cancer progression
por: Yang, Yongyong, et al.
Publicado: (2023)

Editorial: Epigenetics in prostate cancer
por: Baniahmad, Aria, et al.
Publicado: (2023)

Editorial: The role of transcription factors, stem cell markers and epigenetics contributing to chemoresistance in brain cancers
por: Castresana, Javier S., et al.
Publicado: (2023)

Epigenetic regulation of cutaneous T-cell lymphoma is mediated by dysregulated lncRNA MALAT1 through modulation of tumor microenvironment
por: Guo, Wei, et al.
Publicado: (2022)

Editorial: Mechanisms of Epigenetics and Genetics in Leukemogenesis
por: Li, Yonghui, et al.
Publicado: (2022)

Editorial: Epigenetic Regulation and Tumor Immunotherapy
por: Sun, Hongyin, et al.
Publicado: (2022)

Editorial: Epigenetics and cellular plasticity in glioblastoma
por: Lo, Hui-Wen, et al.
Publicado: (2023)

Interaction of ncRNA and Epigenetic Modifications in Gastric Cancer: Focus on Histone Modification
por: Yang, Qingfan, et al.
Publicado: (2022)

Editorial: Epigenetics and molecular genetics of rare tumors
por: Tognon, Mauro, et al.
Publicado: (2022)

Editorial: Epigenetic insights into diagnostic and therapeutic applications
por: Fratta, Elisabetta, et al.
Publicado: (2023)

Editorial: RNA-Mediated Epigenetic and Transcriptional Regulation
por: Barutcu, A. Rasim, et al.
Publicado: (2022)

The Pathogenic Role of Dysregulated Epigenetic Modifications in Autoimmune Diseases
por: Wu, Haijing, et al.
Publicado: (2019)

Editorial: Overcoming drug relapse and therapy resistance in NSCLC
por: Parakh, Sagun, et al.
Publicado: (2023)

Editorial: Systemic immune dysregulation in malignant disease: Insights, monitoring and therapeutic exploitation
por: Christopoulos, Petros, et al.
Publicado: (2023)

Epigenetic alteration and microRNA dysregulation in cancer
por: Suzuki, Hiromu, et al.
Publicado: (2013)

Editorial: Proteoglycans in the Tumor Microenvironment
por: Brunetti, Jlenia, et al.
Publicado: (2022)

Epigenetic Regulation of Claudin-1 in the Development of Ovarian Cancer Recurrence and Drug Resistance
por: Visco, Zachary R., et al.
Publicado: (2021)

Editorial: New insights into the mechanisms of resistance to anti-cancer drugs
por: Bertoni, Francesco, et al.
Publicado: (2022)

Intersection of Epigenetic and Metabolic Regulation of Histone Modifications in Acute Myeloid Leukemia
por: Dhall, Abhinav, et al.
Publicado: (2019)

Editorial: Epigenetic and metabolic regulation of primary and metastatic brain cancers
por: Gimple, Ryan C., et al.
Publicado: (2023)

Editorial: Genetic/epigenetic mechanisms and related clinical strategy in leukemia
por: Li, Yonghui, et al.
Publicado: (2023)

CUL4B Promotes Temozolomide Resistance in Gliomas by Epigenetically Repressing CDNK1A Transcription
por: Ye, Xiang, et al.
Publicado: (2021)

Comprehensive Transcriptomic Analysis Reveals Dysregulated Competing Endogenous RNA Network in Endocrine Resistant Breast Cancer Cells
por: Gao, Liang, et al.
Publicado: (2020)

Editorial: Impact of Cancer Plasticity on Drug Resistance and Treatment in Solid Tumors
por: Cohen, Pascale A., et al.
Publicado: (2020)

Editorial: Recent advances of drug resistance research in colorectal cancer therapy
por: Ye, Chenyang, et al.
Publicado: (2022)

Editorial: Drug resistance in breast cancer – mechanisms and approaches to overcome chemoresistance
por: Raman, Dayanidhi, et al.
Publicado: (2023)

Transcription Factors and Methylation Drive Prognostic miRNA Dysregulation in Hepatocellular Carcinoma
por: Qin, Shijie, et al.
Publicado: (2021)

Development and Validation of Epigenetic Modification-Related Signals for the Diagnosis and Prognosis of Hepatocellular Carcinoma
por: Lu, Maoqing, et al.
Publicado: (2021)

Dysregulation of Transcription Factor Networks Unveils Different Pathways in Human Papillomavirus 16-Positive Squamous Cell Carcinoma and Adenocarcinoma of the Uterine Cervix
por: Bispo, Saloe, et al.
Publicado: (2021)

Editorial: RNA and RNA modification in the pathogenesis, diagnosis and treatment of cancers
por: Wang, Lihui, et al.
Publicado: (2022)

m6A Modification in Non-Coding RNA: The Role in Cancer Drug Resistance
por: Chen, Chen, et al.
Publicado: (2021)

Editorial: Epigenetic and transcriptional networks underlying ventricular and atrial arrhythmias
por: Zhao, Yuanyuan, et al.
Publicado: (2022)

Editorial: FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Cancer
por: Yoon, Sungpil, et al.
Publicado: (2021)

Editorial: Drug-resistance in cancer cells: A new wine in an old bottle
por: da Fonseca, Leonardo Marques, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7dnisi7sfok8mptbaulffm4ohu